Advertisement
Document › Details
Affimed N.V.. (3/15/18). "Press Release: Affimed to Present Data on AFM24 at AACR Annual Meeting 2018". Heidelberg.
Region | Chicago, IL | |
Country | United States (USA) | |
Organisation | Affimed N.V. (Nasdaq: AFMD) | |
Group | Affimed (Group) | |
Organisation 2 | American Association for Cancer Research (AACR) | |
Product | AFM24 (EGFRwt/CD16A TandAb, Affimed) | |
Product 2 | AACR Annual Meeting 2018 Chicago | |
Person | Ammon (formerly Alexandru), Anca (Ammon Communications 202103 before MorphoSys + Affimed + MacDougall European Office) | |
Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data for the Company’s AFM24 program at the AACR Annual Meeting 2018 in Chicago, IL.
Poster Presentation
Abstract: Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors (#2786)
Session: PO.IM02.11 - Therapeutic Antibodies, Including Engineered Antibodies 2
Date and Time: Monday, April 16, 2018 1:00 PM - 5:00 PM (CT)
Location: McCormick Place South, Exhibit Hall A, Poster Section 34/Board 19, Chicago, IL
Full abstract of the presentation can be accessed on the AACR website at www.aacr.org
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR Phone: +49 6221 64793341 E-Mail: a.alexandru@affimed.com, IR@affimed.com
Record changed: 2023-06-05 |
Advertisement
More documents for Affimed (Group)
- [1] Affimed N.V.. (11/3/22). "Press Release: Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101". Heidelberg & San Diego, CA....
- [2] Affimed N.V.. (11/1/22). "Press Release: Affimed to Present at the 2022 Jefferies London Healthcare Conference". Heidelberg....
- [3] Affimed N.V.. (9/1/22). "Press Release: Affimed to Present at Upcoming Investor Conferences". Heidelberg....
- [4] Affimed N.V.. (4/13/22). "Press Release: Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares". Heidelberg....
- [5] Affimed N.V.. (4/12/22). "Press Release: Affimed Announces Proposed Public Offering of Common Shares". Heidelberg....
- [6] Affimed N.V.. (4/10/22). "Press Release: Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting". Heidelberg....
- [7] Affimed N.V.. (4/8/22). "Press Release: Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors". Heidelberg....
- [8] Affimed N.V.. (3/31/22). "Press Release: Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress". Heidelberg....
- [9] Affimed N.V.. (6/16/21). "Press Release: Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board". Heidelberg....
- [10] Affimed N.V.. (1/15/21). "Press Release: Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares". Heidelberg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top